Literature DB >> 480384

Human colon adenocarcinoma cells. III. In vitro organoid expression and carcinoembryonic antigen kinetics in hollow fiber culture.

L P Rutzky, J T Tomita, M A Calenoff, B D Kahan.   

Abstract

Cell line LS174T was established in our laboratory from a primary human colon adenocarcinoma and was serially cultured for 4 years. Following 1 month of culture in perfused hollow fiber matrices, organoid growth reminiscent of the patient's original tumor was observed. The cellular organization was predominantly glandular with mucin located within gland lumina and cells. Glands had irregular brush borders, well-developed junctional complexes, and intracytoplasmic lumina lined with microvilli, features found in adenocarcinoma tissue. Alternate-day determinations of carcinoembryonic antigen (CEA) revealed biphasic kinetics in the extracapillary fluids of the hollow fiber system but not in identically treated monolayer cultures. The initial rate of CEA release was similar to that of monolayer cultures. A significantly accelerated secondary CEA release phase was observed in 10,000- and 50,000-molecular weight (MW)-exclusion fiber cultures (P less than or equal to 0.001 and P = 0.05, respectively). Totals of 43.8 micrograms and 112.6 micrograms CEA were released into the extracapillary fluids of 10,000- and 50,000-MW-exclusion fiber cultures, respectively, which were onefold and 2.3-fold increases, respectively, over monolayer supernatant yields. Most CEA was released during the final days of the secondary phase. In monolayer cultures, maximum CEA release occurred during the stationary phase of growth.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 480384

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

Review 1.  Bioreactor technologies to support liver function in vitro.

Authors:  Mohammad R Ebrahimkhani; Jaclyn A Shepard Neiman; Micha Sam B Raredon; David J Hughes; Linda G Griffith
Journal:  Adv Drug Deliv Rev       Date:  2014-03-05       Impact factor: 15.470

2.  Primary and long term epithelial cell cultures from human fetal normal colonic mucosa.

Authors:  K M Siddiqui; D P Chopra
Journal:  In Vitro       Date:  1984-11

3.  National Pancreatic Cancer Project. Workshop on pancreatic tumor markers.

Authors:  H Z Kupchik; R A Reisfeld; V L Go
Journal:  Dig Dis Sci       Date:  1982-01       Impact factor: 3.199

4.  Characterization of a human colonic adenocarcinoma cell line, LS123.

Authors:  L P Rutzky; B C Giovanella; B H Tom; C I Kaye; P D Noguchi; B D Kahan
Journal:  In Vitro       Date:  1983-02

5.  Carcinoembryonic antigen production by human colorectal adenocarcinoma cells in matrix-perfusion culture.

Authors:  J M Quarles; N G Morris; A Leibovitz
Journal:  In Vitro       Date:  1980-02

6.  Enhanced CEA production associated with aspirin in a culture of CW-2 cells on some polymeric films.

Authors:  A Higuchi; S Uchiyama; M Demura; T Asakura; C S Cho; T Akaike; H Takarada; M Hara
Journal:  Cytotechnology       Date:  1999-11       Impact factor: 2.058

7.  Renal tumouroids: challenges of manufacturing 3D cultures from patient derived primary cells.

Authors:  Agata Nyga; Katerina Stamati; Patricia A Redondo; Tayebeh Azimi; Andrew Feber; Joana B Neves; Rifat Hamoudi; Nadège Presneau; Soha El Sheikh; Maxine G B Tran; Mark Emberton; Marilena Loizidou; Umber Cheema
Journal:  J Cell Commun Signal       Date:  2022-01-31       Impact factor: 5.782

8.  The clinical value of immunohistochemically demonstrable CEA in breast cancer: a possible method of selecting patients for adjuvant chemotherapy.

Authors:  S R Smith; A Howell; A Minawa; J M Morrison
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

9.  Establishment of new ovarian and colon carcinoma cell lines: differentiation is only possible by cytokeratin analysis.

Authors:  V J Möbus; R Moll; C D Gerharz; D G Kieback; W Weikel; G Hoffmann; R Kreienberg
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.